|
ИСТИНА |
Войти в систему Регистрация |
ИСТИНА ЦЭМИ РАН |
||
Recombinant RBD of the SARS-CoV-2 Spike Protein: Production in Escherichia coli Cells, Binding to Antibodies, and Antiviral Activityстатья
Информация о цитировании статьи получена из
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 20 февраля 2024 г.
- Авторы: Gromova M.S., Gromov A.V., Grunina T.M., Lyashchuk A.M., Galushkina Z.M., Subbotina M.E., Esmagambetov I.B., Ryabova E.I., Prokofiev V.V., Kovyrshina A.V., Ilyukhina A.A., Shelkov A.Y., Karyagina A.S., Lunin V.G.
- Журнал: Molecular Genetics, Microbiology and Virology
- Том: 38
- Номер: 2
- Год издания: 2023
- Издательство: Allerton Press Inc.
- Местоположение издательства: United States
- Первая страница: 86
- Последняя страница: 94
- DOI: 10.3103/s0891416823020052
- Аннотация: The recombinant protein 6His-RBDshort was synthesized in Escherichia coli cells, including the RBM (receptor-binding motif) of SARS-CoV-2 Spike protein (330-527 а.а.). The two-stage chromatographic purification of the recombinant protein 6His-RBDshort followed by multi-stage refolding was performed. Enzyme immunoassay demonstrated effective interaction of the recombinant protein 6His-RBDshort with virus neutralizing antibodies, comparable to eukaryotic protein eRBD. The antiviral activity study showed inhibition of SARS-CoV-2 virus replication after Vero E6 cells treatment with 6His-RBDshort (45.1%) and eRBD (42.8%) proteins. The recombinant protein 6His-RBDlong obtained in the same work, including a longer RBD region, did not interact with virus neutralizing antibodies and did not inhibit the replication of the SARS-CoV-2 virus. The developed recombinant protein 6His-RBDshort is a promising drug for therapeutic use as an ACE2 receptor blocker after additional studies.
- Добавил в систему: Карягина-Жулина Анна Станиславовна